NEWS
- Diadem Reports New Data Showing Its AlzoSure® Predict Blood Test Can Accurately Identify “Rapid Progressors” Who Will Develop Alzheimer’s Disease Within Two Years
Milan, Italy and San Francisco, California, January 9, 2023
DiademSpA,acompany developing the first blood-based test for the early prediction ofprogression toAlzheimer’s disease (AD),today announced that its researchers have developed computational methods that enable itsAlzoSure®Predictprognostic technology toaccuratelyidentify individuals who will rapidly progress to AD within twoyears’ time.More than95%of the patients above thenew computational “cutoff”used to define“rapidprogressors”were shown toprogress to AD withintwoyears’time, regardless of their baseline diagnosis.
- At CTAD 2022 Diadem highlights how its Alzosure® Predict Prognostic Blood Test for Alzheimer’s Disease will Help Patients and Facilitate Development of New Therapies
Milan, ITALY and San Francisco, USA – December 5th, 2022
Diadem SpA, a company developing the first blood-based test for the early prediction of progression to Alzheimer’s disease (AD), presented clinical data at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference highlighting the accuracy and clinical utility of its AlzoSure® Predict prognostic blood test for Alzheimer’s Disease (AD), setting the stage for commercialization in the U.S. beginning in 2023.
- Diadem builds out executive team as it prepares for commercialisation of its Alzosure Predict® Prognostic Test for Alzheimer’s Disease
Milan, ITALY – November 21, 2022
Diadem SpA, (or Diadem US, Inc.) a company developing the first blood-based test for the early prediction of progression to Alzheimer’s disease (AD), today announced key additions to its senior management team.
- Diadem Partners with Dementias Platform UK to Advance Diagnosis and Treatment of Alzheimer’s Disease
Milan, ITALY – May xx, 2022
Diadem SpA, a company developing AlzoSure® Predict, the first blood-based test for the early prediction of progression to Alzheimer’s disease (AD), today announced ….
- Diadem Announces Publication of Clinical Study Confirming Its AlzoSure® Predict Blood Test Can Accurately Predict Progression to Alzheimer’s Disease Six Years Before Diagnosis
Milan, ITALY – May 16, 2022
Diadem SpA today announced publication of the results of a clinical validation study of its AlzoSure® Predict prognostic blood test for Alzheimer’s disease (AD) ….
- Diadem Announces Publication of Peer-Reviewed Article Describing How Post-Translational Modifications of p53 Variants May Contribute to Development of Alzheimer’s Disease
Milan, ITALY – April 28, 2022
Diadem SpA, a company developing the first blood-based test for the early prediction of progression to Alzheimer’s disease (AD), today announced …
- Diadem Announces First Closing of €10 Million Equity Financing for Its AlzoSure® Predict Prognostic Blood Test for Alzheimer’s Disease
Milan, Italy, March 28, 2022
Diadem SpA, a company developing the first blood-based test for the early prediction of Alzheimer’s disease (AD), today announced the closing of the first tranche ….
- Diadem Presents Data at AD/PD™ 2022 International Conference Demonstrating Its New AlzoSure® Confirm Blood Test Has the Potential to Accurately Diagnose Alzheimer’s Disease
Milan, ITALY and Barcelona, SPAIN – March 22, 2022
Diadem srl, a company developing blood-based tests for the early prediction and diagnosis of Alzheimer’s disease (AD), today announced that …
- European Investment Bank to Provide a €7.5 Million Loan to Support Further Research and Development of Diadem’s AlzoSure® Predict Blood Test for Alzheimer’s Disease
Luxembourg City (Luxembourg) and Brescia (Italy) – March 07, 2022
The European Investment Bank (EIB) has awarded a €7.5 million loan to Diadem Srl, a company developing the first blood-based prognostic test for the early prediction of Alzheimer’s disease …
- Diadem Receives CE-IVD Certification to Market Its AlzoSure® Predict Prognostic Blood Test for the Early Prediction of Alzheimer’s Disease in Europe
Brescia, Italy – February 28, 2022
Diadem Srl today announced CE IVD certification for its AlzoSure® Predict prognostic blood test for the early prediction of Alzheimer’s disease …
- FDA Grants Breakthrough Device Designation to Diadem’s AlzoSure® Predict Prognostic Blood Test for the Early Prediction of Alzheimer’s Disease
San Francisco, CA – January 18, 2022
Diadem U.S., Inc.,(a subsidiary of Diadem Srl) a company developing the first blood-based test for the early prediction of Alzheimer’s disease (AD), today announced …
- Presentation at Clinical Trials on Alzheimer’s Disease Meeting Highlights How Diadem’s AlzoSure® Predict Can Enable AD Clinical Trials and Screening for Early Detection of AD
Milan, ITALY and Boston, MA, USA – November 15, 2021
Diadem srl, a company developing the first blood-based test for the early prediction of Alzheimer’s disease (AD), today reported that it presented …
- Diadem Presents Data at 22nd International Conference on Alzheimer’s Drug Discovery Highlighting Its Blood-Based Biomarker Test Is 84% Concordant with Amyloid Brain Imaging
Milan, ITALY – October 6, 2021
Diadem srl, a company developing the first blood-based test for the early prediction of Alzheimer’s disease, today announced release …
- Diadem Announces New Publication Reviewing How Post Translational Modifications of p53 Variants May Contribute to Development of Alzheimer’s Disease
Milan, ITALY – September 23, 2021
Diadem srl, a company developing the first blood-based test for the early prediction of progression to Alzheimer’s disease (AD), today announced release …
- Diadem Announces Publication of Clinical Data Showing Its AlzoSure® Biomarker Test Accurately Predicts Progression to Alzheimer’s Disease Six Years Before Diagnosis
Milan, ITALY – August 26, 2021
Diadem srl, a company developing the first blood-based test for the early prediction of progression to Alzheimer’s disease (AD), today announced results …
- Diadem Awarded Patent in China for Its AlzoSure® Prognostic Biomarker Technology that Accurately Predicts Progression to Alzheimer’s Disease
Milan, ITALY – August 4, 2021
Diadem srl, a company developing the first blood-based test for the early prediction of Alzheimer’s disease (AD), today announced that its AlzoSure® prognostic…
- Diadem Presents Clinical Validation Interim Data Confirming Its AlzoSure® Prognostic Biomarker Test Accurately Predicts Progression to Alzheimer’s Disease
Milan, ITALY – May 18, 2021
Diadem srl, a company developing the first blood-based test for the early prediction of Alzheimer’s disease (AD), today …
- Diadem Presents New Data at AAIC® Symposium Showing Its Blood-Based Biomarker Test Accurately Predicts Progression to Alzheimer’s Disease 7 Years Before Symptoms Occur
Milan, ITALY – May 13, 2021
Diadem srl, a company developing the first blood-based test for the early prediction of Alzheimer’s disease (AD), today …
- New Scientific Publications Show Diadem’s Blood-Based AlzoSure® Biomarker Test Can Predict Which Patients Will Progress to Alzheimer’s Disease Years Before Symptoms Occur
Milan, ITALY – February 01, 2021
Diadem srl, a company developing the first blood-based test for the early prediction of Alzheimer’s disease (AD), today announced the publication…
- Diadem Presents Clinical Data and Commercialization Plans for Its AlzoSure® Prognostic Biomarker Test at 2020 Alzheimer’s Disease International Conference
Milan, ITALY – December 11, 2020
Diadem srl, a company developing the first blood-based test for the early prediction of Alzheimer’s disease (AD), today reported that it hosted a Symposium on its prognostic biomarker…
- Diadem Names Dr. Tamas Bartfai Chair of Its Medical Advisory Board
Milan, ITALY – December 1, 2020
Diadem srl, a company developing the first blood-based test for the early prediction of Alzheimer’s disease (AD), today announced that noted neuroscientist and Alzheimer’s disease…
- Development of Blood-Based Alzheimer’s Prognostic Propels Diadem to Finalist Status for Both the Gaetano Marzotto Company Prize and 2030 Social Impact Special Prize
Milan, ITALY – November 16, 2020
pool of 600 applicants. The companies were analyzed by experts representing relevant public, private, financial, technological and specialist…
- Diadem Names Clinical Diagnostics Industry Veteran Paul Kinnon as CEO
Milan, ITALY – October 19, 2020
Diadem srl, a company developing the first blood-based test for the prediction of early onset Alzheimer’s disease, today announced that Paul Kinnon has been named…